Blog
RSS FeedPosted by Michael Wonder on 23 Feb 2022
PHARMAC’s clinical experts recommend funding Trikafta
23 February 2022 - PHARMAC today announces its clinical advisory committee PTAC has recommended funding cystic fibrosis treatment Trikafta with ...
Posted by Michael Wonder on 16 Feb 2022
PHARMAC publishes experts’ advice and seeks views on access criteria for COVID-19 treatments
16 February 2022 - PHARMAC is releasing meeting records of its COVID-19 Treatments Advisory Group and seeking feedback on the patient ...
Posted by Michael Wonder on 14 Feb 2022
PHARMAC proposing to widen access to funded medicines
14 February 2022 - PHARMAC has issued a consultation today on proposals to widen access to two medicines, rituximab and zoledronic ...
Posted by Michael Wonder on 08 Feb 2022
Free EpiPen campaign returns in response to overwhelming demand
8 February 2022 - Allergy New Zealand and Pub Charity have relaunched the successful FundaPen campaign to deliver 3,355 free lifesaving ...
Posted by Michael Wonder on 31 Jan 2022
New Zealand Pharmaceutical Schedule - 1 February 2022 update
1 February 2022 - The Febuary 2022 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 27 Jan 2022
Shortage of prescription infant formula worries parents
28 January 2022 - A shortage of prescription infant formula has parents worried about how they will feed their babies. ...
Posted by Michael Wonder on 26 Jan 2022
Former bowel cancer patient calls for NZ to fund drug she says saved her life
26 January 2022 - A woman with bowel cancer who was told she may have two years to live says ...
Posted by Michael Wonder on 26 Jan 2022
PHARMAC confirms access criteria for COVID-19 treatments
26 January 2022 - PHARMAC has today confirmed the access criteria for two COVID-19 treatments – baricitinib and casirivimab with ...
Posted by Michael Wonder on 17 Jan 2022
PHARMAC - 2021 in review
17 January 2022 - PHARMAC released its Year in Review for 2021 in late December. ...
Posted by Michael Wonder on 22 Dec 2021
PHARMAC publishes experts’ advice and seeks views on patient access criteria for COVID-19 treatments
22 December 2021 - PHARMAC is releasing the October meeting records of their COVID-19 clinical expert advisory group and seeking feedback ...
Posted by Michael Wonder on 18 Dec 2021
PHARMAC bundle deal life-giving for some cancer patients, but medics say NZ still 'playing catch up' for best treatments
16 December 2021 - About 100 patients with stage 3 lung cancer stand to gain extra years of life from ...
Posted by Michael Wonder on 16 Dec 2021
PHARMAC looking to fund medicines for lung and ovarian cancer
16 December 2021 - PHARMAC is considering funding a bundle deal which would give New Zealanders more effective treatment options for ...
Posted by Michael Wonder on 14 Dec 2021
PHARMAC still stalled on lung cancer drug
14 December 2021 - Lung cancer sufferers are still waiting on PHARMAC to reverse a decision made more than a ...
Posted by Michael Wonder on 12 Dec 2021
Where to now for PHARMAC?
10 December 2021 - The interim report of the review of PHARMAC has just been published, with the thrust of ...
Posted by Michael Wonder on 08 Dec 2021
Funding Keytruda for melanoma but not for lung cancer is racist, health advocates say
8 December 2021 - PHARMAC has been accused of institutional racism and breaching the Treaty of Waitangi for funding drugs ...